PORTLAND, KS, UNITED STATES, February 13, 2025 /EINPresswire / -- Rheumatoid arthritis is an autoimmune disorder, w ...

AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ...

The vagus nerve, a complex bundle of 200,000 fibers connecting the brain to vital organs, has remained a medical enigma for ...

AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

Turmeric shots are a wellness drink that may offer many health benefits for their antioxidant and anti-inflammatory effects, ...

Researchers discovered a previously unknown mechanism that may drive tissue damage and a new target for drug discovery.

Discover how high-content imaging identifies drug responses and disease activity in rheumatoid arthritis, paving the way for personalized treatments.

Rheumatoid arthritis (RA) is an autoimmune disorder affecting millions worldwide, causing chronic inflammation, debilitating ...

All physicians are faced with the challenge of how to help patients with no approved therapies for their diseases. What are ...

It’s still not clear whether vagus nerve stimulation will be as effective as drug treatment, says Dr. Andrew Ko, a ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.